



REATA

Two-Year Durability of Improvements in eGFR with Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension: The LARIAT Study

Colin J. Meyer, MD; Murali M. Chakinala, MD, FCCP; Melanie P. Chin, PhD; Daniel W. Coyne, MD; Jeremy Feldman, MD; Angie Goldsberry, MS; Peter A. McCullough, MD, MPH; Megan O'Grady, PhD; Fernando Torres, MD; Ronald J. Oudiz, MD; Keith Ward, PhD; R. James White, MD, PhD

BACKGROUND

BARDOXOLONE METHYL

- Bardoxolone methyl (BARD) is an oral, once-daily investigational therapy that activates Nrf2 and suppresses NF- κ B; *in vitro*, BARD activates cellular metabolism¹
- In prior clinical studies that enrolled over 2,000 patients, BARD increased eGFR^{2,3}


KIDNEY FUNCTION IN PAH

- Pulmonary arterial hypertension (PAH) is characterized by inflammation and vascular remodeling in the lung as well as impaired mitochondrial function in multiple organs⁴⁻⁷
- CKD complicates management of right heart failure in PAH⁸
- Kidney dysfunction is a powerful poor prognostic factor in PAH especially in those with scleroderma⁸⁻¹⁰

LARIAT STUDY

- Phase 2 trial assessing the safety and efficacy of BARD relative to placebo with various etiologies of pulmonary hypertension (PH)
 - Part 1: placebo-controlled study
 - Patients received BARD (2.5, 5, 10, or 20 mg; median 10 mg) or placebo
 - 16-week duration
 - Part 2: Open-label extension study
 - Patients received BARD (up to 20 mg)
- Primary efficacy results of change from baseline in 6-minute walk distance have been previously presented¹¹

This post-hoc analysis investigates the long-term safety and efficacy of BARD on eGFR in cohorts of patients with PAH over a 2-year time period




METHODS


- Patients with a confirmed diagnosis of PAH were randomized to receive bardoxolone methyl for 16 weeks or placebo, followed-by an open-label extension
- Patients with BNP > 200 pg/mL or eGFR < 45 mL/min/1.73 m² at baseline were excluded
- Estimated GFR was calculated from serum creatinine data using the Modification of Diet in Renal Disease (MDRD) equation
- A paired t-test was used to assess change from baseline in eGFR after treatment with bardoxolone methyl for 16, 56, and 104 weeks

RESULTS: CHANGE IN eGFR

- Part 1: BARD increased eGFR from baseline and relative to placebo after 16 weeks of treatment (p<0.001)
- Part 2: Increases in eGFR with BARD were durable for up to 2 years of treatment (p<0.001)



Distribution of eGFR Changes



PATIENT DEMOGRAPHICS

Parameter	Placebo (n=10)	Bardoxolone Methyl (n=46)	All (n=56)
Mean (± SD) Age (yrs)	48.9 ± 10.5	52.2 ± 12.8	51.6 ± 12.4
Female (n, %)	8 (80%)	37 (80%)	45 (80%)
Mean (± SD) Weight (kg)	75 ± 13.8	80.8 ± 19.1	79.7 ± 18.3
Mean (± SD) BMI (kg/m ²)	27.8 ± 5	30.2 ± 6.1	29.8 ± 5.9
PAH Etiology (n, %)			
Idiopathic	5 (50%)	24 (52%)	29 (52%)
CTD	3 (30%)	15 (33%)	18 (32%)
Anorexigen associated	2 (20%)	4 (9%)	6 (11%)
Heritable	0	2 (4%)	2 (4%)
Not specified	0	1 (2%)	1 (2%)
WHO/NYHA Function (n, %)			
Class II	7 (70%)	36 (78%)	43 (77%)
Class III	3 (30%)	10 (22%)	13 (23%)
Mean (± SD) Baseline 6MWD (m)	424 ± 72	427 ± 90	426 ± 87
Baseline eGFR, mean ± SD (mL/min/1.73 m ²)	86.9 ± 17.4	71.7 ± 17.2	75.6 ± 21.1
eGFR ≥ 90 mL/min/1.73 m ² , n (%)	4 (40%)	7 (15%)	11 (20%)
Mean time (± SD) since PAH diagnosis (yrs)	3.7 ± 2.2	4.6 ± 4.1	4.4 ± 3.8
Mean PAH Background Therapies	2.1 ± 0.6	1.8 ± 0.5	1.9 ± 0.5
PDE5i (n, %)	8 (80%)	35 (76%)	43 (77%)
ERA (n, %)	9 (90%)	37 (80%)	46 (82%)
Both ERA and PDE5i (n, %)	8 (80%)	27 (59%)	35 (63%)

SAFETY

- Most commonly reported AE was muscle spasms, which are associated with creatine kinase reductions
- No drug-related serious adverse events occurring in > 1 patient treated with BARD for up to 2 years

ADVERSE EVENTS THROUGH 16 WEEKS OF TREATMENT

Preferred Term	Number (%) of Patients	
	Placebo (n=10)	Bardoxolone Methyl (n=46)
Muscle Spasms	1 (10%)	10 (22%)
Nausea	2 (20%)	8 (17%)
Upper Respiratory Tract Infection	1 (10%)	8 (17%)
Headache	2 (20%)	7 (15%)
Diarrhoea	1 (10%)	7 (15%)
Fatigue	1 (10%)	6 (13%)
Decreased Appetite	1 (10%)	5 (11%)
Gastroesophageal Reflux Disease	0 (0%)	5 (11%)
Urinary Tract Infection	0 (0%)	5 (11%)
Pain In Extremity	0 (0%)	5 (11%)

AEs occurring in ≥ 5 patients

CONCLUSION

- Consistent with previous studies of bardoxolone methyl in patients with chronic kidney disease, bardoxolone methyl significantly increased eGFR in patients with PAH
- The increase in eGFR with bardoxolone methyl was sustained through two years of treatment

REFERENCES

- Sporn, MB *et al.* *J Nat Prod* 2011; 74:537-45.
- Pergola *et al.* *N Engl J Med* 2011;365:327-36.
- Chin *et al.* *Am J Nephrol* 2018;47(1):40-47.
- Oudiz *et al.* *Am J Resp and Crit Care Med* 2017; 195:A6896.
- Sutendra G, Michelakis ED. *Cell Metab* 2014;20:827-39
- de Man *et al.* *EurRespJ* 2009;34:669-75.
- Batt *et al.* *Am J RespCell MolBiol* 2014;50:74-86.
- Price *et al.* *PLoSOne* 2013;8:e75415.
- Nickel *et al.* *Pulmonary Circulation* 2017;7(1):38-54.
- Chakinala, *et al.* *I Heart Lung Transplant* 2017; doi.org/10.1016/j.healun.2017.10.028.
- Campo *et al.* *Am J Respir Crit Care Med* 2010; 182: 252-260.

DISCLOSURES

CM, MC, AG, MO, and KW are employees of Reata Pharmaceuticals. RO and MC are consultants to Reata Pharmaceuticals and receive research support from Reata Pharmaceuticals. FT is a speaker for Reata Pharmaceuticals. PM and AW have no financial disclosures. RJW serves as a paid consultant to Reata Pharmaceuticals with full disclosure to the University of Rochester.